2019年哮喘和冠状病毒病风险:背景个人病例系列和队列研究报告了关于COVID-19对哮喘患者的脆弱性和死亡风险的相互矛盾的结果。研究问题哮喘患者感染、住院或COVID-19临床结果较差的风险更高吗?方法在2019年12月1日至2021年7月11日期间，基于包括世卫组织COVID-19数据库在内的5个主要数据库，对对照组(非哮喘)的研究进行系统回顾和meta分析。采用Sidik-Jonkman随机效应荟萃分析汇集患病率和风险比。在COVID-19阳性病例中，有51项研究合并哮喘患病率为8.08% (95% CI 6.87-9.30)。感染COVID-19的风险比为0.83 (95% CI 0.73-0.95, p=0.01);住院治疗1.18 (95% CI 0.98-1.42, p=0.08);ICU住院患者1.21 (95% CI 0.97-1.51, p=0.09);使用呼吸机的患者为1.06 (95% CI 0.82-1.36, p=0.65)，使用呼吸机的患者为0.94 (95% CI 0.76-1.17;P =0.58)。 Subgroup analyses by continent revealed a significant difference in risk of acquiring COVID-19, ICU admission, ventilator use and death between the continents.Interpretation The risk of being infected with SARS-CoV-2 was reduced compared to the non-asthma group. No statistically significant differences in hospitalisation, ICU admission and ventilator use were found between groups. Subgroup analyses showed significant differences in outcomes from COVID-19 between America, Europe and Asia. Additional studies are required to confirm this risk profile, particularly in Africa and South America where few studies originate.The risk of being infected with SARS-CoV-2 was reduced compared to the non-asthma group. No significant differences in hospitalisation, ICU admission, ventilator use and mortali were found between groups. %U //www.qdcxjkg.com/content/erj/early/2021/07/29/13993003.01209-2021.full.pdf